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Objective. We investigated the use of miconazole among female prostitutes in Costa Rica as well as the distribution of vaginal yeasts
and the susceptibility pattern to azoles of strains obtained from this population. Our intention was to relate a frequent use of
miconazole to occurrence of vaginal yeasts resistant to azoles. Methods. Vaginal samples were taken from 277 patients that have
previously used azoles. Vaginal swabs were obtained for direct microscopy and culture. Yeast isolates were identiﬁed by germ tube
test and assimilation pattern. Susceptibility testing was determined using a tablet diﬀusion method. Results. The number of clinical
Candidaisolates(onefromeachpatient)was57(20.6%).C.albicanswasthepredominantspecies(70%),followedbyC.parapsilo-
sis (12%), C. tropicalis (5.3%), C. glabrata and C. famata (3.5% each), C. krusei, C. inconspicua and C. guilliermondii (1.7% each).
The majority of vaginal Candida isolates were susceptible to ketoconazole (91%), ﬂuconazole (96.5%), and itraconazole (98%).
A lower susceptibility of some isolates to miconazole (63%) was observed as compared to the other azoles tested. Moreover, the
strains, nonsusceptible to miconazole, were more often obtained from patients that have used this antifungal at least four times
within the last year before taking the samples as compared to those with three or less treatments (P<. 01). Conclusion. An indis-
criminate use of miconazole, such as that observed among female prostitutes in Costa Rica, results in a reduced susceptibility of
vaginal yeasts to miconazole but not to other azoles.
Copyright © 2007 Norma T. Gross et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Candida may be either a commensal or a pathogen of the
vagina, a fact which indicates that changes in the vaginal mi-
croenvironment are generally necessary for Candida to in-
duce pathological changes associated with clinical symptoms
[1]. Vulvovaginal candidosis (VVC) is a common cause of
vaginal discharge, soreness, vulval burning, dysuria and local
pruritus in women. C. albicans is the most common etiolog-
ical agent of VVC, but other species such as C. glabrata, C.
krusei,a n dC. tropicalis are also encountered [1–3].
Depending on the age, locality, and social economical
status, the frequency of vaginal yeast isolates has been re-
ported to be between 5% and 48.4% in healthy nonpregnant
women [4–6]. During pregnancy, an increase of 7.8% and
67.8% of yeast vaginal isolates has been reported [7, 8]. A
study in Jordan revealed a diﬀerent distribution of strains of
Candida spp. among pregnant, infertile, and (nonpregnant,
fertile) healthy controls [6].
Azoles are antifungal drugs frequently used for treatment
of VVC. There is evidence, however, of an increased azole
resistance among isolates of Candida spp. isolated from pa-
tients with VVC [9, 10]. Non-C. albicans are generally more
resistant to azoles than are C. albicans strains [11]. Partic-
ularly in patients with VVC, several authors have found an
increased prevalence of C. glabrata due to a selection mech-
anism related to the frequent use of imidazoles (ketocona-
zole and miconazole) [5, 12, 13]. VVC caused by a C. al-
bicans strain, resistant to ﬂuconazole after azole treatment,
has been reported [14]. Several authors using genetic analy-
sis have shown that the most common factor seen in recur-
rent VVC is the development of resistance during treatment
[15, 16].
In the present work, we wanted to study the occurrence
of vaginal yeasts, their species distribution, and the suscep-
tibility pattern to azoles of the strains obtained from female
prostitutes who attended at a public clinic in San Jos´ e, Costa
Rica. Since an indiscriminate use of self-prescribed azoles is2 Infectious Diseases in Obstetrics and Gynecology
frequent in this population, our aim of this study was also to
determine if this behavior might cause resistance of infecting
yeasts to these antifungal drugs.
2. SUBJECTS AND METHODS
2.1. Patients
Vaginal samples were collected during 24 months from 277
prostitutes examined at the Control Center of AIDS and Sex-
ual Transmitted Diseases, Caja Costarricence del Seguro So-
cial, San Jos´ e, Costa Rica. The study included patients with
or without clinical symptoms of vulvovaginitis (pruritus, dy-
suria, or vulval burning). All patients had previously taken
miconazole (≥ 1−≤3a n d≥ 4−≤10 times) within the
last year before the clinical samples were taken. Each patient
completed a questionnaire about age, history of diabetes,
and use of contraceptives, vaginal douche, and antimicrobial
agents. Vulvovaginal symptoms and ﬁndings at the gyneco-
logical examination such as type of secretion, vulval oedema,
and vulval erythema were recorded.
2.2. Samplingprocedure
Two sterile swabs were obtained from each patient. One
of the swabs was inoculated into Sabouraud dextrose
agar containing penicillin (0.01gmL−1) and streptomycin
(0.03gmL−1). The plates were then incubated at room tem-
perature (25–30◦C) for 5 days. The second swab was ﬁrst
streaked into a glass slide for Gram preparation, and then
placed in a tube containing 0.5mL of sterile 0.85% saline so-
lution. A wet saline mount and a 20% potassium hydroxide
preparation of the sample were then mounted on glass slides
for the observation of trichomonas and yeast cells and/or hy-
phae in a light microscope using low magniﬁcation.
2.3. Identiﬁcationoftheyeastisolates
Yeast cultures were identiﬁed as C. albicans by development
of germ tubes in human serum. Germ tube-negative isolates
were identiﬁed by their assimilation pattern with the ID 32C
identiﬁcation system for yeasts (BioMerieux, France). The
identiﬁed yeast isolates were maintained in distilled water at
5◦C.
2.4. Susceptibilitytesting
The tablet diﬀusion method (Neo-Sensitabs, ROSCO Diag-
nostica, Taastrup, Denmark [17, 18]) was performed for all
isolates according to the manufacturer’s instructions. An in-
oculum containing approximately 5 × 105 colony forming
units (CFU) mL−1 (McFarland 0.5, diluted 1:1 with 0.85%
saline solution or diluted 1:10 in the case of C. krusei)w a s
prepared. One mL of this suspension was poured onto the
agarsurface(ﬂooding)andexcessliquidwasremovedimme-
diately with a pipette. Thereafter, the open plates were dried
at37◦Cfor15minutesandthetabletswereplacedontheagar
surface. The azoles tested were miconazole, ketoconazole,
ﬂuconazole, and itraconazole. Plates were incubated at 37◦C
for 18 hours and the inhibition zones were measured. C. al-
bicans ATCC 64548 and ATCC 64550 were included as the
quality controls for susceptibility testing. Isolates were clas-
siﬁed as susceptible, intermediate, and resistant according to
themanufacturer’srecommendationsasfollows:formicona-
zole, ketoconazole, and ﬂuconazole, susceptible = ≥ 20mm,
intermediate = 12–19mm, resistant = ≤ 11mm and for itra-
conazole, susceptible = ≥ 15mm, intermediate = 10–14mm,
resistant = no zone.
Yeast isolates classiﬁed by the tablet diﬀusion method as
intermediate or resistant to ﬂuconazole were tested accord-
ing to the microdilution method proposed by the European
Committee on Antibiotic Susceptibility (EUCAST)[19]. Flu-
conazole powder was provided by Pﬁzer Inc. (Stockholm,
Sweden). Results for miconazole were only obtained by the
tablet diﬀusion method since susceptibility testing to this an-
tifungal has not yet been standardized by either the M-27 A2
reference method of NCCLS (now CLSI, Clinical Laboratory
Standard Institute) [20] or the EUCAST.
3. RESULTS
3.1. Patients
Of the 277 patients examined, 106 were symptomatic (38%)
and 171 were asymptomatic (62%). Among patients with
symptoms, 48% had only one of the symptoms (itching, vul-
var burning, or dysuria), 32% and 20% had two and three
symptoms, respectively (Table 1). The age range of the pa-
tients was from 18 to 50 years and the mean age was 30 years.
Only 12 patients (4.3%) were taking antibacterial treatment.
Two patients (0.72%) were diabetic. Vaginal douche was a
common practice in 122 (44%) of the patients. For fertility
protection, some of the patients used more than one method
with 105 patients taking estrogens, 16 using intrauterine de-
vices, 118 using condoms, 32 were protected by salpingec-
tomy and 70 unprotected.
3.2. Identiﬁcationoftheyeastisolates
The number of patients with clinical Candida isolates (each
patient was counted only once) was 57 (20.6%). Of these iso-
lates 36 were found among patients with symptoms and 21
fromthosewhowereasymptomatic(Table 1).C.albicanswas
the predominant species (70%), followed by C. parapsilosis
(12%). The identity of all Candida species isolated is given in
detail in Table 2. It was found that only 36 (34%) out of 106
vaginal samples obtained from patients with vulvovaginitis
were culture positive for Candida spp. Thirty-one patients
with symptoms had negative yeast cultures and reported the
use of condom. Twenty-nine patients with symptoms had
negative yeast cultures and reported the use of acetic acid
in vaginal douche. Trichomonas vaginalis and Gram-negative
pleomorphic bacilli were reported in 6 and 2 patients with
negative yeast cultures, respectively.Norma T. Gross et al. 3
Table 1: Candida isolates in patients without (n = 171) or with diﬀerent symptoms of vulvovaginitis (n = 106) all with previous miconazole
treatment.
Symptoms Number of patients Number of Candida isolates Number of miconazole nonsusceptible strains
Itching 45 — —
Vulval burning or dysuria 6 — —
Itching, vulval burning, and dyuria 21 — —
Summary of patients with symptoms 106 36 6
Patients without symptoms 171 21 13
Table 2: Azole nonsusceptibility of Candida isolates from vagina of women with or without vulvovaginitis and with previous miconazole
treatment. Total number of isolates = 57.
Yeast Number of Fluconazole Itraconazole Ketoconazole Miconazole
isolates nonsusceptible nonsusceptible nonsusceptible nonsusceptible
C. albicans 40 — — — 10
C. parapsilosis 7 ——— 5
C. tropicalis 3 ——— 2
C. glabrata 2 1122
C. famata 2 ————
C. krusei 1 1—1 1
C. inconspicua 1 ——— 1
C. guillermondii 1 ————
T o t a l n u m b e r 5 7 213 2 1
3.3. Susceptibilitytesting
Among the diﬀerent species of Candida, resistance to ﬂu-
conazole (MIC, >64µg/mL, EUCAST method) was observed
with one isolate of C. krusei and another one of C. glabrata.
The C. krusei isolate had zone diameters for ﬂuconazole, ke-
toconazole,andmiconazole ≤ 11mm(resistant),and22mm
for itraconazole (susceptible). The C. glabrata isolate had
zone diameters for ﬂuconazole, ketoconazole, and micona-
zole ≤ 11mm and no zone for itraconazole (resistant to all
azoles tested). Three isolates intermediate to ketoconazole
were observed. The isolated strains were C. albicans (2) and
C.glabrata(1).Astomiconazole,resistantisolateswereiden-
tiﬁed as C. parapsilosis (2), C. albicans (1), and C. glabrata
(1). The strains intermediate to miconazole were C. albicans
(9), C. parapsilosis (3), C. tropicalis (2), C. glabrata (1), and
C. inconspicua (1).
Tables 2 and 3 summarize the in vitro susceptibility of
57 Candida strains to ﬂuconazole, itraconazole, ketocona-
zole, and miconazole as determined by a tablet diﬀusion test.
Table 1 shows that miconazole resistant strains were found
to a high degree among asymptomatic as well as among pa-
tients with symptoms. In Table 3, the isolates were divided
into two groups, those from women treated with micona-
zole ≤ 3 and those treated ≥ 4 times during the last year
before taking the samples. When the two groups containing
22 (≤ 3) and 35 isolates (≥ 4) were compared, 3 (13.6%) and
18 isolates (51.4%), respectively, were nonsusceptible to mi-
conazole. The diﬀerence is signiﬁcant (P<. 01 Fisher’s exact
test [21]).
4. DISCUSSION
In Costa Rica, the use of miconazole is very frequent among
prostitutes as a treatment for vaginal candidasis. It is also a
common belief among this group of women that the con-
stant use of antifungal will prevent yeast vaginal infection.
The present study was therefore undertaken to examine the
occurrence and species distribution of vaginal yeasts and to
evaluate susceptibility of yeast isolates recovered from vagi-
nalsamplestomiconazole.Susceptibilitytestingtoketocona-
zole, ﬂuconazole, and itraconazole was also performed. In
contrast to other azoles, miconazole possesses two mecha-
nisms of action and yeasts are most often found to remain
susceptible even after repeated exposures [22]. Our study
shows however that after more than three treatment periods
miconazole resistant strains are frequently found.
Our particular patient population always chose micona-
zole and used it even without clinical symptoms of vulvo-
vaginitis. The misuse of this drug is reﬂected by the fact
that resistant Candida strains were found to a high degree
among asymptomatic patients (Table 1). The reasons for the
choice of miconazole are that this drug, in Costa Rica, is
available over-the-counter and that it is less expensive than
other azoles. A control group, that is patients that had taken
repeated treatments (more than three times) of azoles other
than miconazole, was not possible to obtain. However, our
patients with three treatments or less can be considered as
controls to those with four or more treatments. A signiﬁ-
cantly higher number of nonsusceptible yeast isolates were
found in this latter group than among the controls (Table 3).4 Infectious Diseases in Obstetrics and Gynecology
Table 3: Azoles susceptibility pattern of Candida spp. isolated from vagina of women with or without vulvovaginitis with previous micona-
zole treatment (≤ 3o r≥ 4 times). Total number of isolates = 57 (consisting of 22 and 35 isolates from women taken miconazole ≤ 3a n d
≥ 4 times, respectively, during the last year before taking the samples). When the two groups (≤ 3a n d≥ 4) were compared as to miconazole
nonsusceptibility, the P value was < .01.
Resistant Intermediate Nonsusceptible (resistant + intermediate) Susceptible
≤ 3 ≥ 4 ≤ 3 ≥ 4 ≤ 3 ≥ 4 ≤ 3 ≥ 4
Fluconazole 1 1 0 0 1 1 20 35
Itraconazole 1 0 0 0 1 0 20 36
Ketoconazole 1 1 2 1 3 2 18 34
Miconazole 1 4 2 14 3 18 19 17
A previous study in female sexual workers revealed that
themostfrequentlyisolatedvaginalyeastwasC.albicans,fol-
lowed by C. glabrata [10]. In the general population, sev-
eral studies also indicate thatC. albicans predominates over
other species. C. glabrata is the second one most common,
but other species such as C. krusei, C. parapsilosis, C. tropi-
calis, C. guilliermondii, C. kefyr are also encountered [2, 3, 6].
In accordance with these previous authors, in our study C.
albicans was the dominant vaginal isolate. However, C. para-
psilosis was the second one most common, followed by C.
tropicalis and then by C. glabrata.
Clinical symptoms such as itching, vulvar burning, and
dysuria are not always indicative of VVC [1] ,w h i c hi si n
agreement with our results. Among possible explanations
for these ﬁndings are contact dermatitis or allergic reactions
probably related to the use of condom or other devices such
as acetic acid used in vaginal douche. Other causative agents
could be involved, such as Trichomonas vaginalis or Gram-
negative pleomorphic bacilli. These observations are impor-
tant to consider for adequate treatment of vulvovaginitis.
In a previous in vitro susceptibility study of vaginal iso-
lates in Jordan, miconazole nitrate was less eﬀective as com-
pared to amphotericin B, nystatin, and chlorhexidine. In
the study, however, no other azoles were examined [6]. The
susceptibility to ﬂuconazole of C. albicans and C. glabrata
isolated from female prostitutes with vulvovaginitis was
e v a l u a t e di na n o t h e rs t u d y[ 10]. These authors reported a
greater susceptibility to ﬂuconazole for C. albicans com-
paredtoC.glabrata.Theyisolatedone(4.3%)resistantstrain
of C. glabrata and four dose-dependent susceptible strains
(17.3%).
The reference method for susceptibility testing to azoles
(ﬂuconazole, ketoconazole, and itraconazole) is the docu-
ment M27-A2, proposed by CLSI [20]. However, suscepti-
bility testing to miconazole has not been standardized. The
method used in the present study, the tablet diﬀusion (Neo-
sensitabs), is an alternative method which oﬀers susceptibil-
ity testing to miconazole with interpretation of the zone di-
ameters for local infections. Thus, the results of our study
were analyzed in accordance with this method.
Concerning the susceptibility of the vaginal isolates to
azoles, our data indicate that the majority of the isolates were
susceptible to the azoles evaluated. Resistance to ﬂuconazole
was observed with one isolate of C. krusei. The isolate was
also resistant to ketoconazole and miconazole, but not to
itraconazole. It is well-established that C. krusei is intrinsi-
cally resistant to ﬂuconazole and ketoconazole [23, 24]. As to
itraconazole, C. krusei is usually susceptible [21]. One isolate
of C. glabrata also exhibited resistance to ﬂuconazole and the
rest of the azoles tested. It is known that C. glabrata can de-
velop resistance to ﬂuconazole as a primary and secondary
mechanism [24].
Inthepresentstudy,miconazolewhichwastheazoleused
by all patients showed the lowest percentage of susceptibility
(63%). It is also of interest that 9% of the isolates were re-
sistant and 28% were intermediate to miconazole. Further,
most of the nonsusceptible strains to miconazole were ob-
tained from women that had been taking this antifungal four
or more times during the last year before taking the clinical
samples. In our study, there was only one C. albicans resis-
tant isolate. However, among the isolates classiﬁed as inter-
mediate, there were 9 C. albicans. Our ﬁnding is in agree-
ment with previous observations that the majority of yeast
isolates that develop resistance while on treatment are C. al-
bicans [25–28]. Taking these observations into account, it is
recommended to advice this group of women not to take an-
timicrobials indiscriminatively.
In conclusion, the great majority of vaginal Candida iso-
lates exhibited susceptibility to ketoconazole, ﬂuconazole,
and itraconazole. However, a tendency for lower susceptibil-
ity of some isolates to miconazole was observed as compared
to the other azoles tested, a ﬁnding that could be related to
the abuse of miconazole treatment by female prostitutes in
Costa Rica.
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